Probiotic consortiums: Structure and antagonistic activity against opportunistic bacteria and human normobiota (using the example of Escherichia coli) in vitro

Background. Using probiotic preparations based on consortia of microorganisms not only helps to restore the balance of the intestinal microbiota, but also increases the therapeutic effect of probiotics. Promising sources for obtaining probiotic consortia are milk products that have undergone natural fermentation with the help of spontaneously formed microbial consortia.

The aim. To study the structure of five microbial consortia with probiotic properties from naturally fermented milk products and to assess in vitro their antagonistic activity against opportunistic bacteria and a representative of the human normobiota – Escherichia coli.

Materials and methods. The structure of bacterial consortia was analyzed by sequencing methods. The antagonistic activity of the consortia was assessed by the disk diffusion method.

Results. It has been established that the studied microbial consortiums are represented by Enterococcus spp. and Streptococcus spp. bacteria. In consortiums No. 1, No.  2, and No.  3, Enterococcus bacteria dominated, while in consortiums No.  4 and No. 5, Streptococcus dominated. Antagonistic activity was shown against four isolates of opportunistic bacteria: Klebsiella pneumoniae No.  493, Enterobacter hormaechei No. 372, Staphylococcus aureus No. 4 and Pseudomonas aeruginosa No. 25 IMB, as well as against one representative of the human normobiota – Escherichia coli No. 495. The highest growth delay zone is found in E. coli No. 495 isolate. Three test cultures (K. pneumoniae No. 509, E. coli ATCC25922 and P. aeruginosa No. 3 IMB) exhibited more dense growth around probiotic consortia.

Conclusion. The results of the study showed that the effect of probiotic consortia differing in the composition of microorganisms can be neutral and bactericidal. The presence of antagonistic activity in the studied microbial consortia against multiresistant isolates of opportunistic bacteria is a prospect for creating probiotics with antibacterial properties.

1. Savinova YuS, Belkova NL, Semenova NV, Rychkova LV. History, current trends and prospects for the development of pro- and prebiotic drugs in Russia and abroad. Acta biomedica scientifica. 2022; 7(5-1): 211-227. (In Russ.). doi: 10.29413/ABS.2022-7.5-1.23

2. Tselipanova EE. Florin® Forte is a domestic multi-component sorbed probiotic drug. Glavnyy vrach Yuga Rossii. 2020; 2(72): 31-32. (In Russ.).

3. Zandanova TN. Probiotic properties study of bacterial concentrate. Storage and Processing of Farm Products. 2022; 3: 109-119. (In Russ.). doi: 10.36107/spfp.2022.311

4. Begunova AV, Savinova OS, Moiseenko KV, Glazunova OA, Rozhkova IV, Fedorova TV. Characterization and functional properties of lactobacilli isolated from kefir grains. Applied Biochemistry and Microbiology. 2021; 57(4): 362-373. (In Russ.). doi: 10.31857/S0555109921040036

5. Nesterova EY, Syromyatnikov MY, Popov VN. Evaluation of the bacterial composition of sour cream using high-throughput sequencing. Proceedings of the Voronezh State University of Engineering Technologies. 2021; 83(3-89): 129-134. (In Russ.). doi: 10.20914/2310-1202-2021-3-129-134

6. Lokachuk MN, Khlestkin VK, Savkina OA, Kuznetzova LI, Pavlovskaya EN. Change in the microbiota of dense rye starter during long-term maintenance. Khleboprodukty. 2020; 11: 33-37. (In Russ.). doi: 10.32462/0235-2508-2020-29-11-33-37

7. Voropaeva NM, Nemchenko UM, Sitnikova KO, Savilov ED, Chemezova NN, Grigorova EV, et al. Frequency of strains with multiple antibiotic resistance in the structure of opportunitistic pathogens. Acta biomedica scientifica. 2022; 7(5-1): 145-153. (In Russ.).doi: 10.29413/ABS.2022-7.5-1.16

8. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A laboratory manual. Cold Spring Harbor Lab. Press; 1989.

9. Determination of the sensitivity of microorganisms to antimicrobial drugs: Guidelines. Moscow: Federal Center for State Sanitary and Epidemiological Surveillance of the Ministry of Health of Russia; 2021. (In Russ.).

10. Rudenko P, Vatnikov Yu, Sachivkina N, Rudenko A, Kulikov E, Lutsay V, et al. Search for promising strains of probiotic microbiota isolated from different biotopes of healthy cats for use in the control of surgical infections. Pathogens. 2021; 10(6): 667. doi: 10.3390/pathogens10060667

11. Punchenko EV, Morozova OV, Eremeeva NB. New possibilities of using probiotic strain Enterococcus faecium L3. Problems in Medical Mycology. 2022; 24(2): 121. (In Russ.)

12. Ermolenko EI, Kotyleva MP, Tsapieva AN, Karaseva AB, Bui T, Suvorov AN. Irritable bowel syndrome therapy in Vietnam with probiotic enterococci. Experimental and Clinical Gastroenterology. 2021; 12: 35-43. (In Russ.). doi: 10.31146/1682-8658-ecg-196-12-35-43

13. Markakiou S, Gaspar P, Johansen E, Zeidan AA, Neves AR. Harnessing the metabolic potential of Streptococcus thermophilus for new biotechnological applications. Curr Opin Biotechnol. 2020; 61: 142-152. doi: 10.1016/j.copbio.2019.12.019

14. Bormotova EA, Gupalova TV, Suvorov AN. Method for creating a recombinant strain of enterococcus L3-SARS based on biologically active strain Enterococcus faecium L3. Russian Journal for Personalized Medicine. 2023; 3(1): 64-71. (In Russ.). doi: 10.18705/2782-3806-2023-3-1-64-71

15. Afanasova EN, Bochanova EN, Gordina OV, Berdiev ShA, Ivanova OV. Enterococcus: Modern importance for medical practice. Modern Problems of Science and Education. 2022; 2: 144. (In Russ.). doi: 10.17513/spno.31555

16. Ermolenko EI, Kotyleva MP, Tsapieva AN, Karaseva AB, Bui Thi Lan An, Bui Thi Huong, et al. Effects of autoprobiotic enterococci of various species on the intestinal microbiota of Hanoi residents during therapy irritable bowel syndrome. Gastroenterologiya Sankt-Peterburga. 2020; 1-2: 82. (In Russ.).